Reprint
Novel Treatment Strategies for Glioblastoma
Edited by
December 2021
280 pages
- ISBN978-3-0365-2599-0 (Hardback)
- ISBN978-3-0365-2598-3 (PDF)
This book is a reprint of the Special Issue Novel Treatment Strategies for Glioblastoma that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
This book is a compilation of articles that brings together current knowledge from an international team of contributors who are dedicated investigators exploring novel strategies for the treatment of glioblastoma. These articles describe some of the latest concepts that will provide students, researchers and clinicians with an overview of the therapeutic approaches being developed in the field of neuro-oncology to combat this deadly disease.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
glioblastoma; glioma; temozolomide; radiotherapy; immunotherapy; novel therapy; personalized treatment; drug repurposing; glioma; glioblastoma; invasion; invadopodia; ion channels; drug repurposing; gene therapy; glioblastoma; glioma; viral vectors; glioblastoma; brain tumor; nanomedicine; cancer stem cell; targeted therapy; brain cancer; cell cycle; differentiation; glioblastoma; proliferation; RAS; SRGAP2; stem cell; TP53; glioblastoma multiforme; GBM; nerve/glial antigen 2; NG2; CK2; CX-4945; proliferation; migration; CRISPR/Cas9; anticancer; glioblastoma; anti-angiogenesis; thyrointegrin αvβ3; PEG; triazole tetrac; P-bi-TAT; P-m-TAT; tetrac; glioblastoma; glioma; one-carbon metabolism; de novo purine synthesis; metabolic reprogramming; metabolic treatment; glioblastoma; immunotherapy; vaccine; immune checkpoint inhibitors; chimeric antigen receptor (CAR) T cells; glioblastoma (GB); prolyl-oligopeptidase (POP); vascular endothelial growth factor (VEGF); transforming growth factor-β (TGF-β); angiopoietin (Ang); endothelial nitric oxide synthase (eNOS); glioblastoma; newly diagnosed glioblastoma; recurrent glioblastoma; GBM; new trial design; glioblastoma; drug-inducible gene expression; Mardepodect; Regorafenib; drug targets; tumor antigens; glioblastoma; renin–angiotensin system; pluripotent stem cells; organoids; cancer stem cells; cancer stem cell niche; tumor microenvironment; n/a